Cervical cancer screening in low-resource settings: A cost-effectiveness framework for valuing tradeoffs between test performance and program coverage

International Journal of Cancer

Volumn 137, Issue 9, 2015, Pages 2208-2219

  Campos, Nicole G ^a   Castle, Philip E ^b,c   Wright, Thomas C ^d   Kim, Jane J ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Global Coalition Against Cervical Cancer   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d Department of Medicine   (United States)

Author keywords

cancer screening; decision analysis; HPV DNA tests; human papillomavirus; uterine cervical neoplasms

Indexed keywords

ACETIC ACID; VIRUS DNA;

ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER SCREENING; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HEALTH CARE PLANNING; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; INTERMETHOD COMPARISON; LOSS TO FOLLOW UP; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MONTE CARLO METHOD; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGRAM COST EFFECTIVENESS; PROGRAM COVERAGE; SENSITIVITY ANALYSIS; SIMULATION; UGANDA; UTERINE CERVIX CANCER; VISUAL INSPECTION WITH ACETIC ACID; WART VIRUS; ALPHAPAPILLOMAVIRUS; EARLY DIAGNOSIS; ECONOMICS; GENETICS; INCIDENCE; MASS SCREENING; MOLECULAR DIAGNOSIS; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ALPHAPAPILLOMAVIRUS; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INCIDENCE; MASS SCREENING; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 84939254043     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29594     Document Type: Article

References (41)

1. Ferlay J, Soerjomataram I, Ervik M, et al., GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer, 2013.
2. Kitchener HC, Castle PE, Cox JT,. Chapter 7: achievements and limitations of cervical cytology screening. Vaccine 2006; 24Suppl3: S3/63-70.
3. Paavonen J, Naud P, Salmeron J, et al., Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301-14.
4. Villa LL, Costa RL, Petta CA, et al., High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 l1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95: 1459-66.
5. United States Food and Drug Administration. "FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV." December 10, 2014. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm426485. Accessed on March 20, 2015.
6. Sankaranarayanan R, Nene BM, Shastri SS, et al., HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 1385-94.
7. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, et al., Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 2005; 353: 2158-68.
8. Sankaranarayanan R, Esmy PO, Rajkumar R, et al., Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 2007; 370: 398-406.
9. Campos NG, Kim JJ, Castle PE, et al., Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in eastern Africa. Int J Cancer 2012; 130: 2672-84.
10. World Health Organization. WHO Guidelines for Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention. Geneva: World Health Organization, 2013.
11. Zhao FH, Lin MJ, Chen F, et al., Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from china. Lancet Oncol 2010; 11: 1160-71.
12. Qiao YL, Sellors JW, Eder PS, et al., A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural china. Lancet Oncol 2008; 9: 929-36.
13. Jeronimo J, Bansil P, Lim J, et al., A multicountry evaluation of careHPV testing, visual inspection with acetic acid, and papanicolaou testing for the detection of cervical cancer. Int J Gynecol Cancer 2014; 24: 576-85.
14. Shastri SS, Mittra I, Mishra GA, et al., Effect of via screening by primary health workers: randomized controlled study in Mumbai, India. J Natl Cancer Inst 2014; 106: dju009
15. Gravitt PE, Rositch AF,. HPV self-testing and cervical cancer screening coverage. Lancet Oncol 2014; 15: 128-9.
16. Castle PE, Rausa A, Walls T, et al., Comparative community outreach to increase cervical cancer screening in the Mississippi delta. Prev Med 2011; 52: 452-5.
17. Racey CS, Withrow DR, Gesink D,. Self-collected HPV testing improves participation in cervical cancer screening: a systematic review and meta-analysis. Can J Public Health 2013; 104: e159-66.
18. Belinson JL, Du H, Yang B, et al., Improved sensitivity of vaginal self-collection and high-risk human papillomavirus testing. Int J Cancer 2012; 130: 1855-60.
19. Arbyn M, Verdoodt F, Snijders PJ, et al., Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol 2014; 15: 172-83.
20. Goldie SJ, Kim JJ, Kobus K, et al., Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 2007; 25: 6257-70.
21. Kim JJ, Kuntz KM, Stout NK, et al., Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 2007; 166: 137-50.
22. Kim JJ, Kobus KE, Diaz M, et al., Exploring the cost-effectiveness of HPV vaccination in vietnam: insights for evidence-based cervical cancer prevention policy. Vaccine 2008; 26: 4015-24.
23. Kim JJ, Campos NG, O'Shea M, Diaz M, Mutyaba I., Model-based impact and cost-effectiveness of cervical cancer prevention in Sub-Saharan Africa. Vaccine 2013; 31S: F60-72.
24. Campos NG, Burger EA, Sy S, et al., An updated natural history model of cervical cancer: derivation of model parameters. Am J Epidemiol 2014; 180: 545-55.
25. Parkin DM, Whelen SL, Ferlay J, et al., Cancer Incidence in Five Continents Vol. I-VIII. Lyon, France: International Association of Cancer Registries CancerBase No. 7, 2005.
26. Odida M, de Sanjose S, Quint W, et al., Human papillomavirus type distribution in invasive cervical cancer in Uganda. BMC Infect Dis 2008; 8: 85
27. Gold MR., Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
28. Tan-Torres Edejer T, Baltussen R, Adam T, et al., eds. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Geneva, Switzerland: World Health Organization, 2003.
29. World Bank. World Development Indicators. Available at: http://data.worldbank.org/data-catalog/world-development-indicators Accessed on January 6, 2014.
30. World Health Organization. Macroeconomics and Health: Investing in Health for Economic Development: Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization, 2001.
31. Einstein MH, Smith KM, Davis TE, et al., Clinical evaluation of the Cartridge-based GeneXpert human papillomavirus assay in women referred for colposcopy. J Clin Microbiol 2014; 52: 2089-95.
32. Goldhaber-Fiebert JD, Denny LA, De Souza M, et al., Program spending to increase adherence: South African cervical cancer screening. PLoS One 2009; 4: e5691
33. Pretorius RG, Bao YP, Belinson JL, et al., Inappropriate gold standard bias in cervical cancer screening studies. Int J Cancer 2007; 121: 2218-24.
34. Zhao FH, Lewkowitz AK, Chen F, et al., Pooled analysis of a self-sampling HPV DNA test as a cervical cancer primary screening method. J Natl Cancer Inst 2012; 104: 178-88.
35. Dartell MA, Rasch V, Iftner T, et al., Performance of visual inspection with acetic acid and human papillomavirus testing for detection of high-grade cervical lesions in HIV positive and HIV negative tanzanian women. Int J Cancer 2014; 135: 896-904.
36. Ronco G, Dillner J, Elfstrom KM, et al., Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four european randomised controlled trials. Lancet 2014; 383: 524-32.
37. Kuhn L, Wang C, Tsai WY, et al., Efficacy of human papillomavirus-based screen-and-treat for cervical cancer prevention among HIV-infected women. AIDS 2010; 24: 2553-61.
38. Herfs M, Yamamoto Y, Laury A, et al., A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci U S A 2012; 109: 10516-21.
39. Arrossi S, Thouyaret L, Herrero R, et al., Effect of self-collection of HPV DNA offered by community health workers at home visits on uptake of screening for cervical cancer (the EMA study): a population-based cluster-randomised trial. Lancet Glob Health 2015; 3: e85-94.
40. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, et al., Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet 2011; 378: 1868-73.
41. World Health Organization. Prevention of cervical cancer through screening using visual inspection with acetic acid (VIA) and treatment with cryotherapy: a demonstration project in six African countries: Malawi, Madagascar, Nigeria, Uganda, the United Republic of Tanzania, and Zambia. Geneva: World Health Organization, 2012.